在孕前中预测血栓塞:是否需要通用测试?
Ana Belén Gálvez1, Pedro Chorão1,2, Ernesto M Talegón1
1Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
概括
在孕前症 (PE) 患者中,先前的堕胎史和子宫内生长迟缓 (IUGR) 表明血栓友 (TP) 的可能性较低. 没有这些因素的女性可能会受益于TP查.
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 生殖医学 生殖医学
背景情况:
- 孕前 (PE) 与血栓友 (TP) 的关联缺乏共识,需要进一步调查.
- 确定与PE中获得性和遗传性TP相关的特定患者概况至关重要.
- 在PE患者中开发TP概率的预测模型是一个关键的研究缺口.
研究的目的:
- 为了确定与先孕患者获得的和遗传性血栓相关的条件.
- 开发一种预测模型,以预测患有孕前的妇女的血栓友概率.
- 澄清血栓友在孕前中的作用,并确定查的高风险群体.
主要方法:
- 追溯分析95名被诊断患有妊娠前的妇女接受了血栓友爱检测.
- 数据是在2019年5月至2024年5月期间在一个单一中心收集的.
- 多变量分析以确定血栓友的独立预测因子.
主要成果:
- 19%的孕前患者的血栓受试结果为阳性,包括抗脂综合征和遗传因素.
- 子宫内生长迟缓 (IUGR) 和先前的堕胎与血栓友有负面关联.
- 两种因素的TP患病率为0%,一个因素的TP患病率为15%,没有任何因素的TP患病率为32%;较高的TP患病率与较低的胎盘缺陷和早产相关.
结论:
- 堕胎史和IUGR是预产前症中血栓友爱缺失的独立预测因素.
- 没有这些风险因素的孕前患者可能受益于血液学咨询和血栓性查.
- 建议在未来的研究中使用标准化的跨国框架来查妊娠前的血栓友爱症.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
548
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
548
01:13Sensitivity, Specificity, and Predicted Value
144
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
144
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396